Balyasny Asset Management
NGM

Balyasny Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Balyasny Asset Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-360,599
Closed -$573K – 3267
2024
Q1 		$573K Buy
+360,599
New +$535K ﹤0.01% 2000
2023
Q1 		– Sell
-15,600
Closed -$78.3K – 3284
2022
Q4 		$78.3K Buy
+15,600
New +$97.8K ﹤0.01% 2281

Balyasny Asset Management's NGM Position: Q2 2024 in Review

Balyasny Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 360,599 shares — an estimated $573K sold.

Balyasny Asset Management first reported a position in NGM in Q4 2022 and held it in 2 quarters. The position peaked at $573K in Q1 2024. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Balyasny Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 360,599 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $573K.
  • Balyasny Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Balyasny Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $573K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.